Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands. Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), cost... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2015 |
Reihe/Periodikum: | Mangen , M-J J , Rozenbaum , M H , Huijts , S M , van Werkhoven , C H , Postma , D F , Atwood , M , van Deursen , A M M , van der Ende , A , Grobbee , D E , Sanders , E A M , Sato , R , Verheij , T J M , Vissink , C E , Bonten , M J M & de Wit , G A 2015 , ' Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands ' , European Respiratory Journal , vol. 46 , no. 5 , pp. 1407-1416 . https://doi.org/10.1183/13993003.00325-2015 |
Schlagwörter: | COMMUNITY-ACQUIRED PNEUMONIA / POLYSACCHARIDE VACCINE / DISEASE / STRATEGIES / EFFICACY / CHILDREN / DESIGN / HEALTH / IMPACT / TRIAL |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27209329 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/1fc9ca90-c07f-43c0-ab6c-41bd21544c7c |
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) demonstrated the efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in preventing vaccine-type community-acquired pneumonia and vaccine-type invasive pneumococcal disease in elderly subjects. We examined the cost-effectiveness of PCV13 vaccination in the Netherlands. Using a Markov-type model, incremental cost-effectiveness ratios (ICER) of PCV13 vaccination in different age- and risk-groups for pneumococcal disease were evaluated using a societal perspective. Estimates of quality-adjusted life-years (QALYs), costs, vaccine efficacy and epidemiological data were based on the CAPiTA study and other prospective studies. The base-case was PCV13 vaccination of adults aged 65-74 years compared to no vaccination, assuming no net indirect effects in base-case due to paediatric 10-valent pneumococcal conjugate vaccine use. Analyses for age- and risk-group specific vaccination strategies and for different levels of hypothetical herd effects from a paediatric PCV programme were also conducted. The ICER for base-case was 8650 per QALY (95% CI 5750-17100). Vaccination of high-risk individuals aged 65-74 years was cost-saving and extension to medium-risk individuals aged 65-74 years yielded an ICER of (sic)2900. Further extension to include medium- and high-risk individuals aged >= 18 years yielded an ICER of (sic)3100. PCV13 vaccination is highly cost-effective in the Netherlands. The transferability of our results to other countries depends upon vaccination strategies already implemented in those countries.